nach oben

Cellular Oncology

Erschienen in:

01.06.2012 | Original Paper

MMP2 expression is a prognostic marker for primary melanoma patients

verfasst von: Anand Rotte, Magdalena Martinka, Gang Li

Erschienen in: Cellular Oncology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Matrix metalloproteinase 2 (MMP2) is a collagenase, which aids tumor growth and invasion by digesting the extracellular matrix surrounding the tumor tissue. Our study examined MMP2 expression in various stages of melanoma progression and tested the prognostic significance of MMP2 expression. We also analyzed the correlation between p-Akt status and MMP2 expression in melanoma patients.

Methods

Tissue microarray (TMA) and immunohistochemistry were employed to study the expression of MMP2. A total of 482 melanoma (330 primary and 152 metastatic) tumor biopsies and 149 nevi biopsies (49 normal and 100 dysplastic nevi) were used for the analysis. MMP2 expression was correlated with melanoma progression. Kaplan-Meier survival curve and multivariate Cox regression analysis were applied to verify the prognostic significance of MMP2 expression. The correlation between MMP2 and p-Akt expression was analyzed in 92 cases which were common in the present and the previous study on p-Akt expression.

Results

Strong MMP2 expression is significantly increased in primary (25 %) and metastatic melanoma (43 %) compared to normal (5 %) and dysplastic nevi (10 %). Patients with strong MMP2 had significantly poorer survival compared to those with negative-to-moderate MMP2 expression. MMP2 expression could predict the patient survival independent of tumor thickness and ulceration. Furthermore, in our cohort study MMP2 expression was associated with p-Akt status and patient survival.

Conclusions

Strong MMP2 staining is associated with worse survival of melanoma patients and is an independent molecular prognostic factor for primary melanoma.

T.L. Diepgen, V. Mahler, The epidemiology of skin cancer. Br. J. Dermatol. 146(Suppl 61), 1–6 (2002)PubMedCrossRef

A.C. Geller, S.M. Swetter, K. Brooks, M.F. Demierre, A.L. Yaroch, Screening, early detection, and trends for melanoma: current status (2000–2006) and future directions. J. Am. Acad. Dermatol. 57(4), 555–572 (2007). quiz 573–556PubMedCrossRef

A.J. Miller, M.C. Mihm Jr., Melanoma. New Engl. J. Med. 355(1), 51–65 (2006)PubMedCrossRef

H. Tsao, A.J. Sober, Melanoma treatment update. Dermatol. Clin. 23(2), 323–333 (2005)PubMedCrossRef

M.B. Lens, T.G. Eisen, Systemic chemotherapy in the treatment of malignant melanoma. Expert. Opin. Pharmacother. 4(12), 2205–2211 (2003)PubMedCrossRef

C.M. Balch, S.J. Soong, J.E. Gershenwald, J.F. Thompson, D.S. Reintgen, N. Cascinelli et al., Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 19(16), 3622–3634 (2001)PubMed

A.N. Houghton, D. Polsky, Focus on melanoma. Canc. Cell. 2(4), 275–278 (2002)CrossRef

R.M. Turner, K.J. Bell, R.L. Morton, A. Hayen, A.B. Francken, K. Howard et al., Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma. J. Clin. Oncol. 29(35), 4641–4646 (2011)

K.Y. Bilimoria, M.V. Raval, D.J. Bentrem, J.D. Wayne, C.M. Balch, C.Y. Ko, National assessment of melanoma care using formally developed quality indicators. J. Clin. Oncol. 27(32), 5445–5451 (2009)PubMedCrossRef

10.

A.C. Geller, S.M. Swetter, S. Oliveria, S. Dusza, A.C. Halpern, Reducing mortality in individuals at high risk for advanced melanoma through education and screening. J. Am. Acad. Dermatol. 65(5), S87–94 (2011)PubMedCrossRef

11.

C.M. Balch, J.E. Gershenwald, S.J. Soong, J.F. Thompson, M.B. Atkins, D.R. Byrd et al., Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27(36), 6199–6206 (2009)PubMedCrossRef

12.

J.F. Thompson, S.J. Soong, C.M. Balch, J.E. Gershenwald, S. Ding, D.G. Coit et al., Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J. Clin. Oncol. 29(16), 2199–2205 (2011)PubMedCrossRef

13.

M. Bjorklund, E. Koivunen, Gelatinase-mediated migration and invasion of cancer cells. Biochim. Biophys. Acta. 1755(1), 37–69 (2005)PubMed

14.

E.I. Deryugina, J.P. Quigley, Matrix metalloproteinases and tumor metastasis. Canc. Metastasis Rev. 25(1), 9–34 (2006)CrossRef

15.

C.E. Brinckerhoff, J.L. Rutter, U. Benbow, Interstitial collagenases as markers of tumor progression. Clin. Canc. Res. 6(12), 4823–4830 (2000)

16.

U.B. Hofmann, J.R. Westphal, G.N. Van Muijen, D.J. Ruiter, Matrix metalloproteinases in human melanoma. J. Invest. Dermatol. 115(3), 337–344 (2000)PubMedCrossRef

17.

U.B. Hofmann, J.R. Westphal, A.J. Zendman, J.C. Becker, D.J. Ruiter, G.N. van Muijen, Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J. Pathol. 191(3), 245–256 (2000)PubMedCrossRef

18.

T. Turpeenniemi-Hujanen, Gelatinases (MMP-2 and −9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie. 87(3–4), 287–297 (2005)PubMedCrossRef

19.

A.H. Vaisanen, M. Kallioinen, T. Turpeenniemi-Hujanen, Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma. Hum. Pathol. 39(3), 377–385 (2008)PubMedCrossRef

20.

S. Shukla, G.T. Maclennan, D.J. Hartman, P. Fu, M.I. Resnick, S. Gupta, Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int. J. Canc. 121(7), 1424–1432 (2007)CrossRef

21.

V. Vasko, M. Saji, E. Hardy, M. Kruhlak, A. Larin, V. Savchenko et al., Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J. Med. Genet. 41(3), 161–170 (2004)PubMedCrossRef

22.

D.L. Dai, M. Martinka, G. Li, Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J. Clin. Oncol. 23(7), 1473–1482 (2005)PubMedCrossRef

23.

K.M. Sze, K.L. Wong, G.K. Chu, J.M. Lee, T.O. Yau, I. Oi-Lin Ng, Loss of phosphatase and tensin homolog enhances cell invasion and migration through AKT/Sp-1 transcription factor/matrix metalloproteinase 2 activation in hepatocellular carcinoma and has clinicopathologic significance. Hepatology 53(5), 1558–1569 (2011)PubMedCrossRef

24.

H. Lin, R.P. Wong, M. Martinka, G. Li, Loss of SNF5 expression correlates with poor patient survival in melanoma. Clin. Canc. Res. 15(20), 6404–6411 (2009)CrossRef

25.

W. Remmele, H.E. Stegner, Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 8(3), 138–140 (1987)PubMed

26.

A. Vaisanen, P. Kuvaja, M. Kallioinen, T. Turpeenniemi-Hujanen, A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53. Hum. Pathol. 42(8), 1103–1111 (2011)PubMedCrossRef

27.

F. Su, W.D. Bradley, Q. Wang, H. Yang, L. Xu, B. Higgins et al., Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res. 72(4), 969–978 (2012)PubMedCrossRef

28.

J.A. Sparano, P. Bernardo, P. Stephenson, W.J. Gradishar, J.N. Ingle, S. Zucker et al., Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J. Clin. Oncol. 22(23), 4683–4690 (2004)PubMedCrossRef

29.

R.L. Camp, V. Neumeister, D.L. Rimm, A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J. Clin. Oncol. 26(34), 5630–5637 (2008)PubMedCrossRef

Titel: MMP2 expression is a prognostic marker for primary melanoma patients
verfasst von: Anand Rotte
Magdalena Martinka
Gang Li
Publikationsdatum: 01.06.2012
Verlag: Springer Netherlands
Erschienen in: Cellular Oncology / Ausgabe 3/2012
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI: https://doi.org/10.1007/s13402-012-0080-x

Neu im Fachgebiet Pathologie

01.04.2024 | Forensische Traumatologie | CME

Springer Medizin

MMP2 expression is a prognostic marker for primary melanoma patients

Abstract

Background

Methods

Results

Conclusions

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

High HSP27 and HSP70 expression levels are independent adverse prognostic factors in primary resected colon cancer

Cell culture models for studying the development of Barrett’s esophagus: a systematic review

Erratum to: The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer

Genomic aberrations relate early and advanced stage ovarian cancer

Alterations of monocarboxylate transporter densities during hypoxia in brain and breast tumour cells

Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien